Cabozantinib has better effects on tumor angiogenesis and survival than those found with combinations of selective inhibitors of MET and VEGF signaling in the same model, suggesting that AXL or other targets (such as RET, KIT and TIE2) contribute to the efficacy of cabozantinib [57]. The gene discussed is RET; the disease is neoplasm.